IGI Logo

Lincoln Pharmaceuticals is currently trading at Rs. 387.25, up by 4.65 points or 1.22% from its previous closing of Rs. 382.60 on the BSE.

The scrip opened at Rs. 382.60 and has touched a high and low of Rs. 394.90 and Rs. 379.00 respectively. So far 20700 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 407.70 on 16-Sep-2021 and a 52 week low of Rs. 191.40 on 15-Dec-2020.

Last one week high and low of the scrip stood at Rs. 407.70 and Rs. 372.75 respectively. The current market cap of the company is Rs. 780.60 crore.

The promoters holding in the company stood at 37.78%, while Institutions and Non-Institutions held 0.01% and 62.21% respectively.

Lincoln Pharmaceuticals is planning to launch Cephalosporin products soon. The company has acquired a facility in Mehsana, Gujarat. Investment in Cephalosporin plant for Rs 30 crore including crore capacity expansion and modernisation of the facility. Acquisition and further capex will be funded from internal accruals. The company expects commercial operations from March 2022. The plant is expected to contribute sales of around Rs 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.

The acquired facility in Mehsana, Gujarat has been designed as per the PIC's and European Region. The company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021. The company is planning to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic and exports market.

Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products.